RemeGen Co

RemeGen Co EBIT per Employee

The EBIT per Employee of RemeGen Co (688331.SS) as of Oct 26, 2026 is 216,516.09 CNY. In the previous year, EBIT per Employee was -436,871.37 CNY — a change of -149.56% (higher).

EBIT per Employee

216,516.09CNY

YoY

-149.56%

Last updated:

EBIT per Employee of RemeGen Co is 2025 216,516.09 CNY. EBIT per Employee of RemeGen Co was 2024 -436,871.37 CNY. It decreases by -149.56% higher compared to the previous year.

The RemeGen Co EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-72,981.39 CNY
Jan 1, 2019
-126,386.85 CNY
Jan 1, 2020
-212,386.25 CNY
Jan 1, 2021
48,870.95 CNY
Jan 1, 2022
-298,693.34 CNY
Jan 1, 2023
-450,638.93 CNY
Jan 1, 2024
-436,871.37 CNY
Jan 1, 2025
216,516.09 CNY
The RemeGen Co EBIT per Employee history
YEAREBIT per EmployeeYoY
216,516.09CNY-149.56%
-436,871.37CNY-3.06%
-450,638.93CNY+50.87%
-298,693.34CNY-711.19%
48,870.95CNY-123.01%
-212,386.25CNY+68.04%
-126,386.85CNY+73.18%
-72,981.39CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

EBIT per Employee of RemeGen Co is 216,516.09 CNY in 2025.

EBIT per Employee of RemeGen Co changed from -436,871.37 CNY to 216,516.09 CNY, representing a -149.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — RemeGen Co

All Key Metrics — RemeGen Co